▎WuXiEdited by the Kant Content Team

BioAge Labs Announces $170 Million Oversubscribed Series D Financing Led by Sofinnova InvestmentsNew investors include Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, and Amgen Ventures.Andreessen Horowitz (a16z) Bio + Health and other existing investors also participated in this round of financing.

The funds will be used to support BioAge's leading drug candidate azelaprag in Phase 2 clinical development, which will be combined with Eli Lilly's Zepbound (tirzepatide) and other incretin therapies for the treatment of obesity.The research on Zepbound is expected to begin in mid-2024 in collaboration with Eli Lilly's Chorus organization.

Azelaprag is an orally administered apelin receptor agonist., when combined with incretin-based drugs, can significantly promote weight loss and improve body composition.In Phase 1b clinical trials, azelaprag has demonstrated the ability to promote muscle metabolism and increase energy expenditure during bed rest in healthy elderly volunteers, effectively preventing muscle atrophy.Moreover, in preclinical studies, azelaprag doubled the weight loss effects achieved through incretin therapy and further improved body composition and muscle function.

Dr. Kristen Fortney is the co-founder and CEO of BioAge Labs. She has over 10 years of experience developing novel bioinformatics approaches for data-driven research on the mechanisms of aging and age-related diseases. Dr. Eric Morgen is the co-founder and COO of BioAge Labs. He was previously an assistant professor at the University of Toronto, focusing on biomarker discovery in high-dimensional human data.

Everyone is watching

WuXi AppTec provides integrated, end-to-end new drug research and development and production services for the global biopharmaceutical industry, covering areas such as chemical drug R&D and production, biological research, preclinical testing and clinical trial R&D, and cell and gene therapy R&D, testing, and production.If you have relevant business needs, please feel free to click on the image below to fill in the specific information.

▲If you have any business needs, please long press to scan the QR code above, or click "Read more" at the end of the article to access the business对接 platform and fill in your business needs information.

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics. Retrieved February 13, 2024 from https://www.businesswire.com/news/home/20240213546755/en/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.